It broke four earlier this month. Did you miss it? I think some here tried to warn shorty that now was the time to cover. Retail shorty always the last to know.
The fat are getting fatter. If what you suggest is true why is this? Need more options like Belviq.
Thanks diogenes for your interpretation. Shorts can also try and bury a good post.
I think this is the patent application it is referring to.
United States Patent Application 20140213579
Kind Code A1
Sanchez; Matilde ; et al. July 31, 2014
METHOD OF WEIGHT MANAGEMENT
Provided are methods of determining if an individual is a responder to treatment with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof. Also provided are methods for selecting an individual for treatment with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof from a plurality of individuals in need of weight management. Also provided are methods for weight management in an individual in need thereof. Also provided are compounds, compositions, and kits for use in a method of weight management in an individual.
Inventors: Sanchez; Matilde; (Alexandria, VA) ; Shanahan; William R.; (Del Mar, CA)
Name City State Country Type
Shanahan; William R.
Family ID: 47178995
Appl. No.: 14/242442
Filed: April 1, 2014
When this was posted online in July the website stated it would be in a future edition of the Obesity Journal. I do not think it is a mistake that it is getting printed this time of year prior to Obesity Week.
Normally when you put a buy order in you do not do it all in one block. If you do happen to do it in one block the MM's are likely to break it down into smaller blocks.
I do not think it has to do with market cap or OREX or VVUS being larger. I think in the case of ARNA, it has to do with investors looking for opportunity when the market is lagging. But then, what do I know.
I would imagine Dr Huster that did his own small belviq with phen study will have his poster at the conference. That will peak some interest even if the Eisai backed study is not finalized.
That may be true. That is why they will get a partner to pay for it.
Patients still die using the drugs currently on the market. New therapies are necessary.
Did one of the three trials actually show an increase in blood pressure like he says in the article? I like how he said one of the two trial raised blood pressure so I don't think he realizes there where three phase III trials did. From looking at how Lorcaserin alone impacts norepinephrine, it looks like it would always lower blood pressure.
Some here will try and convince you that you should look only at what has happened in the past and not look at what might happen in the future. The weight loss market is huge and while insurance coverage is a big issue, that is improving and changing over time.